Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2000
03/28/2000CA2011238C Pharmaceutical treatment
03/28/2000CA2004885C Anticoagulant peptides
03/28/2000CA1340937C Piperidine compounds and their preparation and use
03/24/2000CA2283021A1 Substituted benzamides
03/23/2000WO2000016231A1 Method for screening and producing compound libraries
03/23/2000WO2000015845A1 T-type calcium channel
03/23/2000WO2000015826A2 Leptin induced genes
03/23/2000WO2000015807A1 Method for down-regulating osteoprotegerin ligand activity
03/23/2000WO2000015802A1 Moraxella catarrhalis basb034 polypeptides and uses thereof
03/23/2000WO2000015801A1 Polynucleotides and polypeptides basb033 from neisseria meningitidis and their uses
03/23/2000WO2000015790A2 Leptin induced genes
03/23/2000WO2000015788A2 Dna sequence encoding oncofetal ferritin protein
03/23/2000WO2000015786A1 Metabotropic gaba receptor complex issued from the central nervous system
03/23/2000WO2000015780A1 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer
03/23/2000WO2000015769A1 Topa
03/23/2000WO2000015768A1 Immune activation by double-stranded polynucleotides
03/23/2000WO2000015766A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
03/23/2000WO2000015666A2 Compositions and methods for the treatment of tumors
03/23/2000WO2000015657A1 Piperizine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and 53
03/23/2000WO2000015641A1 Compounds alkylating specific base sequence of dna and method for synthesizing the same
03/23/2000WO2000015639A1 Carboline derivatives as cgmp phosphodiesterase inhibitors
03/23/2000WO2000015636A1 Dihydrobenzodioxine carboxamide and ketone derivatives as 5-ht4 receptor antagonists
03/23/2000WO2000015634A2 Hiv protease inhibitors
03/23/2000WO2000015614A1 Novel compounds
03/23/2000WO2000015612A1 Aza-bicycles which modulate the inhibition of cell adhesion
03/23/2000WO2000015611A1 Branched alkyl pyrrolidine-3-carboxylic acids
03/23/2000WO2000015609A1 Azetidine derivatives, preparation and medicines containing them
03/23/2000WO2000015563A1 Improved microbial biomass support structure and methods for making same
03/23/2000WO2000015263A1 Expandible microparticle intracellular delivery system
03/23/2000WO2000015261A1 Compositions comprising sympathomimetic amine salts unsuitable for illegal use
03/23/2000WO2000015259A1 Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells
03/23/2000WO2000015246A2 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
03/23/2000WO2000015242A1 REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES
03/23/2000WO2000015240A1 Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
03/23/2000WO2000015239A1 Inhibition of toxic materials or substances using dendrimers
03/23/2000WO2000015237A1 Composition containing rutin and quercetin for preventing or treating elevated blood lipid level-related diseases
03/23/2000WO2000015236A1 Low temperature non-crystallizing liquid xylitol compositions and co-hydrogenation processes for making same
03/23/2000WO2000015235A1 Method of using tetracycline compounds to enhance interleukin-10 production
03/23/2000WO2000015234A1 Compositions comprising corticosteroids for treating sinusitis or otitis media
03/23/2000WO2000015233A1 Compositions for the treatment of male erectile dysfunction
03/23/2000WO2000015232A1 Taurolidine and/or taurultam against infectious ulcer or gastritis
03/23/2000WO2000015231A1 Adenosine a3 receptor modulators
03/23/2000WO2000015230A1 METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION
03/23/2000WO2000015229A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION
03/23/2000WO2000015228A1 Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents
03/23/2000WO2000015227A1 Use of 3,4-dihydro-6, 7-dimethoxy-alpha-phenyl- n,n-bis [(2,3,4-trimethoxyphenyl) ethyl]-1-i soquinolineacetamide in the manufacture of a medicament for the reduction of motor dysfunction
03/23/2000WO2000015226A1 Antihistamines for treating non-infective sinusitis or otitis media
03/23/2000WO2000015225A1 Treatment of depression
03/23/2000WO2000015223A1 Treatment of persistent pain
03/23/2000WO2000015222A1 FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE
03/23/2000WO2000015221A1 Stable ascorbic acid preparation for topical use
03/23/2000WO2000015220A1 A new composition
03/23/2000WO2000015219A1 A new composition
03/23/2000WO2000015218A1 A new composition
03/23/2000WO2000015217A1 A new composition
03/23/2000WO2000015216A1 Therapeutic compositions (ii)
03/23/2000WO2000015215A1 Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
03/23/2000WO2000015214A1 Fc RECEPTOR MODULATORS AND USES THEREOF
03/23/2000WO2000015213A1 Remedal or preventive agent for congestive heart failure
03/23/2000WO2000015212A2 Antifungal activity of dicationic molecules
03/23/2000WO2000015210A2 Use of mycophenol acid and its derivatives for the treatment of virus diseases
03/23/2000WO2000015209A2 REGULATION OF HER2/neu ONCONGENE EXPRESSION BY SYNTHETIC POLYAMIDES
03/23/2000WO2000015208A2 New use of immunosupressants for mmp-mediated diseases
03/23/2000WO2000015206A2 Tryptophanyl ester and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes
03/23/2000WO2000015205A2 Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
03/23/2000WO2000015204A2 Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers
03/23/2000WO2000015203A2 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
03/23/2000WO2000015202A2 Topical application products
03/23/2000WO2000015201A2 Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders
03/23/2000WO2000015200A1 Anti-inflammatory pharmaceutical formulations
03/23/2000WO2000015198A1 Orally administered controlled drug delivery system providing temporal and spatial control
03/23/2000WO2000015197A1 Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
03/23/2000WO2000015196A1 Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
03/23/2000WO2000015195A1 Quick release pharmaceutical compositions of drug substances
03/23/2000WO2000015193A1 Mousse composition
03/23/2000WO2000015188A1 Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution)
03/23/2000WO2000015179A2 Cosmetic composition
03/23/2000WO2000015178A2 Computer implemented pharmacokinetics method and program
03/23/2000WO2000015177A2 Prevention of retinal degeneration in retinitis pigmentosa
03/23/2000WO2000015176A2 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
03/23/2000WO2000015174A2 Bioflavonoid as blood glucose level lowering agent
03/23/2000WO2000015168A1 Topical anti-fungal treatment for dandruff
03/23/2000WO2000015167A1 Anti-inflammatory and antimicrobial uses for bioactive glass compositions
03/23/2000WO2000015051A1 Hydroxycitric acid compositions
03/23/2000WO2000015047A1 Composition containing neohesperidin dihydrochalcone for preventing or treating elevated blood lipid and glucose level-related diseases
03/23/2000WO2000015044A1 Composition containing natural phenolic compounds for preventing or treating elevated blood lipid level-related diseases
03/23/2000WO2000015036A1 Topical dermal antimicrobial compositions
03/23/2000WO2000008013A3 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists
03/23/2000WO2000006135A3 Cholinergic agents in the treatment of presbyopia
03/23/2000WO2000006134A3 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
03/23/2000WO2000001347A3 Formulations for controlling human lice
03/23/2000WO2000000599A3 Composition for the induction of apoptosis in target cells
03/23/2000WO2000000198A8 Piperidine derivatives having effects on serotonin related systems
03/23/2000WO1999066901A3 Transdermal therapeutic system containing hormones and crystallization inhibitors
03/23/2000WO1999065539A9 Tumescent solution
03/23/2000WO1999065493A9 Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
03/23/2000WO1999063983A9 MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS
03/23/2000WO1999061607A3 Antisense oligonucleotides for treating proliferating cells
03/23/2000WO1999061418A3 1α-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF
03/23/2000WO1999061085A3 Method and compositions for treatment of cancers
1 ... 6344 6345 6346 6347 6348 6349 6350 6351 6352 6353 6354 6355 6356 6357 6358 6359 6360 6361 6362 6363 6364 ... 7860